On December 29, 2025 Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse technology using its proprietary Nanosecond Pulsed Field Ablation (nanosecond PFA or nsPFA) energy, reported plans to present at the upcoming 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Pulse Biosciences’ Management is scheduled to present on Wednesday, January 14, 2026, at 3:45pm PT. A live and recorded webcast of the presentation will be available on the "Events Calendar and Presentations" page of the company’s investor website at View Source

(Press release, Pulse Biosciences, DEC 29, 2025, View Source [SID1234661644])

On December 29, 2025 SOFIE Biosciences, an established U.S. manufacturer and developer of radiopharmaceuticals, reported that the first patient has been dosed in one of its two Phase 3 clinical trials evaluating [18F]FAPI-74, a fluorine-18 labeled radiopharmaceutical targeting Fibroblast Activation Protein (FAP), as a novel diagnostic for patients with GI cancers.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are proud of this milestone in the continuing clinical development of FAPI," said Patrick Phelps, President and CEO, SOFIE Biosciences. "FAPI provides a different way to image and identify disease, by targeting cancer-associated fibroblasts in the tumor microenvironment. Dosing the first patient with [18F]FAPI-74 brings us one step closer to addressing vital areas of unmet need in gastric and esophageal cancers and realizing the promise of FAPI PET in precision medicine."

"FAPI-74 is an exciting new advanced PET tracer" said Judith Rose, MD, RadNet’s Director of PET/CT and Research. "RadNet’s experience in PET/CT clinical trials, combined with our national network of advanced imaging capabilities uniquely positions us to support oncology trials to transform cancer diagnosis and treatment. It is an honor to be in the position to have enrolled and imaged, in Los Angeles, the first patient in this important Phase 3 trial. We are looking forward to our ongoing partnership with SOFIE and our clinical partner Helios/The Oncology Institute. "

The FAPI-GO (FAPI in Gastroesophageal Oncology) trial is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in adults with gastroesophageal cancer. The study is planned for 18 sites with an estimated enrollment of 200 subjects over a 24-month period.

The primary study endpoints are sensitivity and specificity for detection of distant metastatic disease (M1). For additional trial details, visit the study page on ClinicalTrials.gov (NCT07217704).

The second Phase 3 study, FAPI-PRO (FAPI in Precision Imaging of Pancreatic Cancer), starting December 2025, is a multi-site, open-label, non-randomized, single dose study to assess the clinical utility of [¹⁸F]FAPI-74 PET/CT in the detection of metastatic disease in adults with Pancreatic Ductal Adenocarcinoma. For additional trial details, visit the study page on ClinicalTrials.gov (NCT07217717).

ABOUT [18F]FAPI-74

[18F]FAPI-74 is the lead fluorine-18 radiolabeled PET tracer in the FAPI family of compounds. It has demonstrated favorable dosimetry, avidity, safety, and a biodistribution profile amenable to detection of FAP-expressing cells in patients with various cancers. This radioligand for imaging is currently optimized for production within SOFIE and its clinical trial partners.

(Press release, Sofie Biosciences, DEC 29, 2025, View Source [SID1234661645])

On December 29, 2025 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, reported that members of its management team will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties may access a live webcast of the fireside chat on the "Investors" section of the company’s website at: View Source The webcast will be archived and available for replay for at least 30 days after the event.

(Press release, 10x Genomics, DEC 29, 2025, View Source [SID1234661646])

On December 29, 2025 Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, and Navigo Proteins GmbH (Halle, Germany), a biopharmaceutical company specializing in the discovery and development of new precision medicine approaches based on the Affilin technology platform, reported the termination of their collaboration agreement signed in May 2024.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Based on both parties’ commitment to scientific excellence and resource optimization, OPM and Navigo have mutually agreed to end this specific collaboration. As a reminder, the partnership between Navigo and OPM was intended to pool their tumor targeting and identification technologies to discover and develop new radiotheranostic agents that are more precise and effective against resistant and metastatic cancers.

The end of this partnership follows a standard prioritization process inherent in advanced research programs. OPM is actively pursuing its innovation strategy in precision medicine and continues to develop its portfolio of assets through its three technology platforms:

Nanocyclix, dedicated to the design and selection of next-generation kinase inhibitors;
OncoSNIPER, for the selection of therapeutic targets using artificial intelligence;
PROMETHE, to design and select radiolabeled biological molecules for systemic radiotherapy.
The COMETE program (moleCular radiOtherapy for METastatic Colorectal and gastric cancErs), which aims to develop a portfolio of radiotheranostic molecules for the treatment of advanced digestive cancers, is continuing. This project, led by OPM, the cancer center (CGFL), and the Institute of Molecular Chemistry at the University of Burgundy (ICMUB, UMR CNRS 6302), all based in Dijon, aims to develop a radiotheranostic candidate through preclinical dosimetry studies. OPM will evaluate other promising vectorization technologies and new target selection work is progressing.

Navigo Proteins will continue the initiated program based on its Affilin and HEAD platform technologies as well as AI assisted de-novo protein design addressing gastric cancers with a strong focus on an accelerated pathway into early testing in human patients.

Philippe Genne, CEO of Oncodesign Precision Medicine, said: "We would like to warmly thank the Navigo team for the quality of the work accomplished. This collaboration has enabled us to explore relevant Affilin leads, even if our collaboration has not demonstrated the expected potential within the program timelines due to the challenges encountered with the first targets selected. Our relationship remains excellent and we continue to move forward with determination on our key programs, including COMETE, a major strategic initiative for OPM."

Henning Afflerbach, CEO of Navigo Proteins GmbH, added: "We have enjoyed working with OPM and maintain a strong mutual appreciation for their core expertise. While further strengthening our commitment to develop innovative radiotheranostics from discovery into the clinic for the benefit of human patients, we wish our partner OPM all the best for the future and remain open to discussions when new opportunities arise."

(Press release, Oncodesign, DEC 29, 2025, View Source [SID1234661647])

On December 29, 2025 Johnson & Johnson (NYSE: JNJ) (the "Company") reported the successful completion of its acquisition of Halda Therapeutics OpCo, Inc. ("Halda"), a clinical-stage biotechnology company with a proprietary Regulated Induced Proximity TArgeting Chimera (RIPTAC) platform to develop oral, targeted therapies for multiple types of solid tumors, including prostate cancer, for $3.05 billion in cash.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This strategic milestone underscores our commitment to redefining cancer treatment with breakthrough science and transformative medicines," said Jennifer Taubert, Executive Vice President, Worldwide Chairman, Innovative Medicine, Johnson & Johnson. "We are excited to formally welcome the talented Halda team to Johnson & Johnson and look forward to working together to achieve our shared goal of eliminating cancer."

With this acquisition, Johnson & Johnson adds HLD-0915, a clinical-stage therapy for prostate cancer, building on the Company’s nearly two decades of innovation in this disease area. HLD-0915 is a once-daily oral therapy that uses a novel RIPTAC platform with a precision cancer cell-killing approach that can overcome mechanisms of resistance to treatment. Additionally, the Company adds several earlier candidates for breast, lung and multiple other tumor types, based on RIPTAC technology, to its leading oncology portfolio. The novel technology may also enable the creation of transformative targeted therapies beyond oncology.

"Johnson & Johnson continuously seeks new ways to meet patient needs and deliver innovative therapies," said John C. Reed, M.D., Ph.D., Executive Vice President, Innovative Medicine, R&D, Johnson & Johnson. "Now that we have finalized this acquisition, we will focus on advancing the potential of this promising pipeline of novel product candidates and harnessing the powerful RIPTAC platform to discover more molecules in oncology and beyond."

The acquisition will be accounted for as a business combination. With the transaction now closing in 2025, Johnson & Johnson expects dilution in Q4 2025 and 2026 earnings. The total dilution to Adjusted Earnings Per Share (EPS) of approximately $0.20 is expected to split equally between 2025 and 2026 based on the latest estimates for the non-recurring charge related to Halda employee equity awards, financing and integration costs. Johnson & Johnson will provide commentary on full year 2026 guidance during the fourth quarter earnings call on Wednesday, January 21, 2026.

(Press release, Johnson & Johnson, DEC 29, 2025, View Source [SID1234661648])